JP2003514818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514818A5 JP2003514818A5 JP2001538906A JP2001538906A JP2003514818A5 JP 2003514818 A5 JP2003514818 A5 JP 2003514818A5 JP 2001538906 A JP2001538906 A JP 2001538906A JP 2001538906 A JP2001538906 A JP 2001538906A JP 2003514818 A5 JP2003514818 A5 JP 2003514818A5
- Authority
- JP
- Japan
- Prior art keywords
- oct
- azabicyclo
- propenamide
- phenylpropenamide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 -CO 2 R 7 Chemical group 0.000 description 26
- 229910052739 hydrogen Inorganic materials 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 206010026749 Mania Diseases 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000025569 Tobacco Use disease Diseases 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 4
- 201000003723 learning disability Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- 0 CC1C(CC2)N(*)C2C1 Chemical compound CC1C(CC2)N(*)C2C1 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- PHZYWNWABJJERF-AATRIKPKSA-N (e)-3-(2-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 PHZYWNWABJJERF-AATRIKPKSA-N 0.000 description 2
- HSTDTPMOYSFAIB-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-OWOJBTEDSA-N 0.000 description 2
- DWEFNEVEZVDWPJ-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 DWEFNEVEZVDWPJ-AATRIKPKSA-N 0.000 description 2
- MENCFQRKJSFDJH-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MENCFQRKJSFDJH-AATRIKPKSA-N 0.000 description 2
- UCRCSZYDUAPEEU-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-iodophenyl)prop-2-enamide Chemical compound IC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 UCRCSZYDUAPEEU-SNAWJCMRSA-N 0.000 description 2
- GERXVMRTEYKZPQ-QPJJXVBHSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GERXVMRTEYKZPQ-QPJJXVBHSA-N 0.000 description 2
- DXSJNKAJPNKROG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-OWOJBTEDSA-N 0.000 description 2
- NBTHWOKIJJBULB-NSCUHMNNSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-NSCUHMNNSA-N 0.000 description 2
- MIWLXSRIICDTEX-HNQUOIGGSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MIWLXSRIICDTEX-HNQUOIGGSA-N 0.000 description 2
- ATNVHCFFVIVLSM-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-2-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-ONEGZZNKSA-N 0.000 description 2
- WMUJNOJUYWXQSG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-3-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-OWOJBTEDSA-N 0.000 description 2
- QDJIWDUPQLKWAA-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-SNAWJCMRSA-N 0.000 description 2
- ODFSOOCVJPIZNA-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-VOTSOKGWSA-N 0.000 description 2
- NZONTOQHVFUZMV-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-ONEGZZNKSA-N 0.000 description 2
- NIJKEAAXBOXSNC-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-OWOJBTEDSA-N 0.000 description 2
- QLXOOYGFEACOIW-BQYQJAHWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-n-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1N(C)C(=O)\C=C\C1=CC=CC=C1 QLXOOYGFEACOIW-BQYQJAHWSA-N 0.000 description 2
- FKRVCWSLGVBIGB-VOTSOKGWSA-N (e)-n-(3-cyano-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C#N)NC(=O)\C=C\C1=CC=CC=C1 FKRVCWSLGVBIGB-VOTSOKGWSA-N 0.000 description 2
- XZVQIURADIYJDK-BQYQJAHWSA-N (e)-n-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C)NC(=O)\C=C\C1=CC=CC=C1 XZVQIURADIYJDK-BQYQJAHWSA-N 0.000 description 2
- HSTDTPMOYSFAIB-ISUDXETCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-ISUDXETCSA-N 0.000 description 2
- DXSJNKAJPNKROG-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-YUKKFKLSSA-N 0.000 description 2
- NBTHWOKIJJBULB-FAAWYNLUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-FAAWYNLUSA-N 0.000 description 2
- MIWLXSRIICDTEX-JWPFQLSCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MIWLXSRIICDTEX-JWPFQLSCSA-N 0.000 description 2
- ATNVHCFFVIVLSM-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-2-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-OOPCZODUSA-N 0.000 description 2
- WMUJNOJUYWXQSG-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-3-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-AORQRIRUSA-N 0.000 description 2
- QDJIWDUPQLKWAA-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-RGDDUWESSA-N 0.000 description 2
- NZONTOQHVFUZMV-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-OOPCZODUSA-N 0.000 description 2
- NIJKEAAXBOXSNC-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-AORQRIRUSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- VTOAFAPBGXLGME-SDNWHVSQSA-N (e)-2,3-diphenylprop-2-enamide Chemical compound C=1C=CC=CC=1/C(C(=O)N)=C\C1=CC=CC=C1 VTOAFAPBGXLGME-SDNWHVSQSA-N 0.000 description 1
- PHZYWNWABJJERF-NFAHFFEMSA-N (e)-3-(2-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 PHZYWNWABJJERF-NFAHFFEMSA-N 0.000 description 1
- RCLFFPCOTKNDRK-ZZXKWVIFSA-N (e)-3-(4-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound C1=CC(N)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 RCLFFPCOTKNDRK-ZZXKWVIFSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-ACCUITESSA-N 0.000 description 1
- MFIWCTVYPBIGQT-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MFIWCTVYPBIGQT-AATRIKPKSA-N 0.000 description 1
- QODFPISBGYJKDV-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-VOTSOKGWSA-N 0.000 description 1
- NVVYTUXHKCMTCD-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 NVVYTUXHKCMTCD-VOTSOKGWSA-N 0.000 description 1
- QOFOUEFCNYRQQX-DUXPYHPUSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QOFOUEFCNYRQQX-DUXPYHPUSA-N 0.000 description 1
- TYYMXUGFPLAOSL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-SNAWJCMRSA-N 0.000 description 1
- OOZULDOHFTVWCS-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-SNAWJCMRSA-N 0.000 description 1
- WHMOYHBOLPOUMR-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-AATRIKPKSA-N 0.000 description 1
- WARWHFWAFGSZMP-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WARWHFWAFGSZMP-ZZXKWVIFSA-N 0.000 description 1
- WUSJALGTATXXGB-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WUSJALGTATXXGB-ZZXKWVIFSA-N 0.000 description 1
- GBLPTBJUUSMWLC-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GBLPTBJUUSMWLC-ZZXKWVIFSA-N 0.000 description 1
- VUDAUVWKTXMSDD-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VUDAUVWKTXMSDD-ZZXKWVIFSA-N 0.000 description 1
- SYJFKEQPXPZQSF-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-iodophenyl)prop-2-enamide Chemical compound C1=CC(I)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 SYJFKEQPXPZQSF-ZZXKWVIFSA-N 0.000 description 1
- LMYLJTJHCPTSPI-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 LMYLJTJHCPTSPI-ZZXKWVIFSA-N 0.000 description 1
- VYJUETVRHRXQFA-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VYJUETVRHRXQFA-AATRIKPKSA-N 0.000 description 1
- HVWIZNLEMLWNOA-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-ACCUITESSA-N 0.000 description 1
- QPOFOAHKDBURCL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-SNAWJCMRSA-N 0.000 description 1
- IFRBWXFNEPBBKA-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-ONEGZZNKSA-N 0.000 description 1
- XELSBDUTKCSMDH-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-4-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-OWOJBTEDSA-N 0.000 description 1
- FJJBZFQDEHWYCR-MEPUESOJSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-diphenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(\C=1C=CC=CC=1)=C\C1=CC=CC=C1 FJJBZFQDEHWYCR-MEPUESOJSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-BYIUCRAPSA-N 0.000 description 1
- MFIWCTVYPBIGQT-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MFIWCTVYPBIGQT-JFDDCEBESA-N 0.000 description 1
- NVVYTUXHKCMTCD-MOEXGYKKSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-MOEXGYKKSA-N 0.000 description 1
- MENCFQRKJSFDJH-GJBLVYBDSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-GJBLVYBDSA-N 0.000 description 1
- QOFOUEFCNYRQQX-OMDKTOEGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 QOFOUEFCNYRQQX-OMDKTOEGSA-N 0.000 description 1
- TYYMXUGFPLAOSL-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-RGDDUWESSA-N 0.000 description 1
- OOZULDOHFTVWCS-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-RGDDUWESSA-N 0.000 description 1
- YAUMYTQGLWXDIH-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 YAUMYTQGLWXDIH-RGDDUWESSA-N 0.000 description 1
- WHMOYHBOLPOUMR-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-JFDDCEBESA-N 0.000 description 1
- WARWHFWAFGSZMP-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WARWHFWAFGSZMP-VFQAQYNWSA-N 0.000 description 1
- WUSJALGTATXXGB-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WUSJALGTATXXGB-VFQAQYNWSA-N 0.000 description 1
- GBLPTBJUUSMWLC-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GBLPTBJUUSMWLC-VFQAQYNWSA-N 0.000 description 1
- VUDAUVWKTXMSDD-GIZXNFQBSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 VUDAUVWKTXMSDD-GIZXNFQBSA-N 0.000 description 1
- GERXVMRTEYKZPQ-RRGWEWPQSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GERXVMRTEYKZPQ-RRGWEWPQSA-N 0.000 description 1
- LMYLJTJHCPTSPI-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 LMYLJTJHCPTSPI-VFQAQYNWSA-N 0.000 description 1
- HVWIZNLEMLWNOA-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-BYIUCRAPSA-N 0.000 description 1
- ODFSOOCVJPIZNA-LFAOLKIESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LFAOLKIESA-N 0.000 description 1
- QPOFOAHKDBURCL-NNTXTVRGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-NNTXTVRGSA-N 0.000 description 1
- IFRBWXFNEPBBKA-XGACYXMMSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-XGACYXMMSA-N 0.000 description 1
- XELSBDUTKCSMDH-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-4-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-YUKKFKLSSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-SICOMBFOSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-SICOMBFOSA-N 0.000 description 1
- NVVYTUXHKCMTCD-FYCOFBDGSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-FYCOFBDGSA-N 0.000 description 1
- MENCFQRKJSFDJH-VBROQKIQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-VBROQKIQSA-N 0.000 description 1
- ODFSOOCVJPIZNA-LQYUOIDQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LQYUOIDQSA-N 0.000 description 1
- MGQYIEIAFOISHD-UVTDQMKNSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-fluoro-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-UVTDQMKNSA-N 0.000 description 1
- QODFPISBGYJKDV-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-SREVYHEPSA-N 0.000 description 1
- HVWIZNLEMLWNOA-QBFSEMIESA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-QBFSEMIESA-N 0.000 description 1
- ODFSOOCVJPIZNA-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-SREVYHEPSA-N 0.000 description 1
- MGQYIEIAFOISHD-LTBFUDJGSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluoro-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-LTBFUDJGSA-N 0.000 description 1
- QODFPISBGYJKDV-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)N[C@@H]1C(CC2)CCN2C1 QODFPISBGYJKDV-XHPSBEMXSA-N 0.000 description 1
- HVWIZNLEMLWNOA-KVNDZABWSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-KVNDZABWSA-N 0.000 description 1
- ODFSOOCVJPIZNA-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-XHPSBEMXSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- BVFZXSDFGCHDCH-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-ynamide Chemical compound C1N(CC2)CCC2C1NC(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-UHFFFAOYSA-N 0.000 description 1
- BVFZXSDFGCHDCH-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-ynamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-HNNXBMFYSA-N 0.000 description 1
- BVFZXSDFGCHDCH-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-ynamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-OAHLLOKOSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9904176A SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | New use |
| SE9904176-6 | 1999-11-18 | ||
| PCT/SE2000/002262 WO2001036417A1 (en) | 1999-11-18 | 2000-11-16 | New use and novel n-azabicyclo-amide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514818A JP2003514818A (ja) | 2003-04-22 |
| JP2003514818A5 true JP2003514818A5 (https=) | 2007-11-15 |
Family
ID=20417766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538906A Pending JP2003514818A (ja) | 1999-11-18 | 2000-11-16 | 新規使用および新規ｎ−アザビシクロ−アミド誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6683090B1 (https=) |
| EP (1) | EP1233964B1 (https=) |
| JP (1) | JP2003514818A (https=) |
| KR (1) | KR20020058014A (https=) |
| CN (1) | CN1217943C (https=) |
| AR (1) | AR031680A1 (https=) |
| AT (1) | ATE298337T1 (https=) |
| AU (1) | AU784400B2 (https=) |
| BG (1) | BG106680A (https=) |
| BR (1) | BR0015624A (https=) |
| CA (1) | CA2389604A1 (https=) |
| CO (1) | CO5261607A1 (https=) |
| CZ (1) | CZ20021692A3 (https=) |
| DE (1) | DE60020994T2 (https=) |
| DK (1) | DK1233964T3 (https=) |
| EE (1) | EE200200251A (https=) |
| ES (1) | ES2242653T3 (https=) |
| HU (1) | HUP0204245A3 (https=) |
| IL (1) | IL149374A0 (https=) |
| IS (1) | IS6385A (https=) |
| MX (1) | MXPA02004911A (https=) |
| NO (1) | NO20022289L (https=) |
| NZ (1) | NZ518571A (https=) |
| PL (1) | PL355867A1 (https=) |
| PT (1) | PT1233964E (https=) |
| SE (1) | SE9904176D0 (https=) |
| SK (1) | SK6772002A3 (https=) |
| UA (1) | UA74172C2 (https=) |
| WO (1) | WO2001036417A1 (https=) |
| ZA (1) | ZA200203316B (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002016357A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001284645A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001282875A1 (en) * | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002016355A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AU2002320958B2 (en) * | 2001-07-06 | 2008-02-28 | Neurosearch A/S | Novel compounds, their preparation and use |
| CA2458375A1 (en) * | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
| CA2462453C (en) * | 2001-10-02 | 2009-07-28 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| JP2005510482A (ja) * | 2001-10-16 | 2005-04-21 | アストラゼネカ・アクチエボラーグ | 線維筋痛症候群の治療方法 |
| JP2005511574A (ja) * | 2001-10-26 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| CA2466375A1 (en) * | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| MXPA04004373A (es) | 2001-11-09 | 2004-08-11 | Upjohn Co | Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades. |
| HUP0501017A3 (en) | 2001-12-14 | 2010-06-28 | Targacept | Methods and compositions for treatment of central nervous system disorders |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| EP1480977A2 (en) | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Substituted aryl compounds for treatment of disease |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| CA2476624A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| CN1656093A (zh) | 2002-05-30 | 2005-08-17 | 神经研究公司 | 3－取代的奎宁环及其用途 |
| US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| US7244745B2 (en) | 2002-08-30 | 2007-07-17 | Memory Pharmaceuticals Corp. | Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| PL377777A1 (pl) * | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
| WO2005037832A2 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US7732607B2 (en) | 2005-08-22 | 2010-06-08 | Anatoly Mazurov | Heteroaryl-substituted diazatricycloalkanes and methods of use thereof |
| WO2007037258A1 (ja) * | 2005-09-28 | 2007-04-05 | Kumamoto University | 注意欠陥・多動性障害の治療薬 |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| US9233106B2 (en) * | 2006-07-12 | 2016-01-12 | Cornell Research Foundation, Inc. | Inhibition of beta-amyloid peptide aggregation |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009046025A1 (en) | 2007-10-01 | 2009-04-09 | Comentis, Inc. | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| KR20100113163A (ko) | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| WO2012177856A2 (en) * | 2011-06-21 | 2012-12-27 | Adispell, Inc. | Cognition modification |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| WO2014202999A1 (en) | 2013-06-21 | 2014-12-24 | Takeda Cambridge Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| JP2017524736A (ja) | 2014-07-11 | 2017-08-31 | アルファーマゲン，エルエルシー | アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物 |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255467B (it) | 1992-07-29 | 1995-11-02 | Dompe Farmaceutici Spa | Ammidi acriliche farmacologicamente attive |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| US5981525A (en) * | 1995-01-10 | 1999-11-09 | Smithkline Beecham Corporation | Indole derivatives useful in the treatment of osteoporosis |
-
1999
- 1999-11-18 SE SE9904176A patent/SE9904176D0/xx unknown
-
2000
- 2000-11-06 AR ARP000105840A patent/AR031680A1/es not_active Application Discontinuation
- 2000-11-16 DK DK00981994T patent/DK1233964T3/da active
- 2000-11-16 CA CA002389604A patent/CA2389604A1/en not_active Abandoned
- 2000-11-16 CZ CZ20021692A patent/CZ20021692A3/cs unknown
- 2000-11-16 EP EP00981994A patent/EP1233964B1/en not_active Expired - Lifetime
- 2000-11-16 DE DE60020994T patent/DE60020994T2/de not_active Expired - Fee Related
- 2000-11-16 KR KR1020027006257A patent/KR20020058014A/ko not_active Ceased
- 2000-11-16 UA UA2002065003A patent/UA74172C2/uk unknown
- 2000-11-16 HU HU0204245A patent/HUP0204245A3/hu unknown
- 2000-11-16 WO PCT/SE2000/002262 patent/WO2001036417A1/en not_active Ceased
- 2000-11-16 CN CN008184216A patent/CN1217943C/zh not_active Expired - Fee Related
- 2000-11-16 IL IL14937400A patent/IL149374A0/xx unknown
- 2000-11-16 NZ NZ518571A patent/NZ518571A/en unknown
- 2000-11-16 PT PT00981994T patent/PT1233964E/pt unknown
- 2000-11-16 AT AT00981994T patent/ATE298337T1/de not_active IP Right Cessation
- 2000-11-16 JP JP2001538906A patent/JP2003514818A/ja active Pending
- 2000-11-16 SK SK677-2002A patent/SK6772002A3/sk unknown
- 2000-11-16 US US10/130,635 patent/US6683090B1/en not_active Expired - Fee Related
- 2000-11-16 ES ES00981994T patent/ES2242653T3/es not_active Expired - Lifetime
- 2000-11-16 BR BR0015624-8A patent/BR0015624A/pt not_active IP Right Cessation
- 2000-11-16 AU AU19073/01A patent/AU784400B2/en not_active Ceased
- 2000-11-16 MX MXPA02004911A patent/MXPA02004911A/es active IP Right Grant
- 2000-11-16 EE EEP200200251A patent/EE200200251A/xx unknown
- 2000-11-16 PL PL00355867A patent/PL355867A1/xx not_active Application Discontinuation
- 2000-11-17 CO CO00087729A patent/CO5261607A1/es not_active Application Discontinuation
-
2002
- 2002-04-25 ZA ZA200203316A patent/ZA200203316B/xx unknown
- 2002-05-09 BG BG106680A patent/BG106680A/bg unknown
- 2002-05-14 NO NO20022289A patent/NO20022289L/no unknown
- 2002-05-15 IS IS6385A patent/IS6385A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514818A5 (https=) | ||
| RU2002118302A (ru) | Новые биарилкарбоксамиды | |
| JP2003512374A5 (https=) | ||
| JP2006507241A5 (https=) | ||
| JP2003513073A5 (https=) | ||
| JP2005527588A5 (https=) | ||
| ES2242653T3 (es) | Nuevo uso y nuevos derivados de n-azabiciclo-amida. | |
| RU2001122812A (ru) | Новые аралкиламины спирофуропиридинов, полезные в терапии | |
| JP2001510194A5 (https=) | ||
| US6500840B2 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease | |
| JP2005539030A5 (https=) | ||
| JP2003513071A5 (https=) | ||
| JP2004532877A5 (https=) | ||
| US7674794B2 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
| RU99128075A (ru) | Производные 8-азабицикло(3,2,1)окт-2-ена и-октана в качестве холинергических лигандов на ацх-рецепторах | |
| JP2005504058A5 (https=) | ||
| RU2009126341A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2.]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ | |
| ZA200502465B (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | |
| ZA200506515B (en) | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | |
| JP2007515486A (ja) | ３−キヌクリジニルヘテロ原子架橋ビアリール誘導体 | |
| ATE524455T1 (de) | Therapeutische mittel zur schmerzbehandlung | |
| JP2007515479A5 (https=) | ||
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| JP2008508365A5 (https=) | ||
| RU2007134414A (ru) | Бензоксазолкарбоксамиды для лечения индуцированной химиотерапией тошноты и рвоты (cini) и синдрома раздраженного кишечника с преобладанием диареи (ibs-d) |